Nextgen Share Discussion Threads

[bobby.ifa] 16/3/2011 10:18

Lady Go Go.
Enjoy your shopping, I'll keep look out.

[lady gaga] 16/3/2011 10:13

Im off out bobby but dont do anything while im gone lol

[lady gaga] 16/3/2011 10:11

And again.

Most just waking up to the news.

Stick with me bobby you wont go wrong. lol

[lady gaga] 16/3/2011 10:10

And up again as I type bobby

[lady gaga] 16/3/2011 10:09

And up again bobby.

[lady gaga] 16/3/2011 10:08

We seem to be on a slow rise back up.

GLTA

[bobby.ifa] 16/3/2011 09:45

Don't think he's the real thing, but certainly is the kiss of death. Leg-over more like.

[lady gaga] 16/3/2011 09:44

lol is that the best u got.

PYC ON THE MOVE GUYS

[hectorp] 16/3/2011 09:30

I bet you are not the real Lady Gaga, but a poor imitation.

[lady gaga] 16/3/2011 09:24

Mean while PYC R LOOKING RLY STRONG.

[lady gaga] 16/3/2011 09:23

This has moved 225% a few weeks ago on nothing.

40% IN THIS SHARE IS NOTHING.

But thats just my view.

[bobby.ifa] 16/3/2011 09:21

How can you say that Gaga?Why the big leg up?

[lady gaga] 16/3/2011 09:13

.45p paid again the next big leg up due soon.

And I mean big leg up.

[lady gaga] 16/3/2011 09:10

LOL

Where r all the long termers.

Me thinks the sold out over the last few days.
Due to japan.

They will want back in now.

15% of shares only around.

[bobby.ifa] 16/3/2011 08:56

45% up "slowly rising". Bloody hell loveabul, hate to think what a correction would be to you.

[loveabul] 16/3/2011 08:51

Slowly rising this may take 1 big jump guys

[bobby.ifa] 16/3/2011 08:03

Can't beat a tiny spread.

[loveabul] 16/3/2011 08:00

A tiny spread looks good

[gstoykov] 16/3/2011 07:46

I think this will move nicely today...offer has risen, lets see if thats what they open at

[stephanie_m] 16/3/2011 07:06

Launch of multiple protein plasma biomarker assay
Share this article
TIDMNGG

RNS Number : 9988C

NextGen Group PLC

16 March 2011

NextGen Sciences launches multiple protein plasma oncology biomarker assay

Ann Arbor, Michigan, US, and London, UK, 16 March 2011 - NextGen Group plc (AIM:NGG) is pleased to announce that its subsidiary NextGen Sciences Inc, a leader in biomarker discovery, measurement and qualification, has launched its first multiple protein (multiplex) assay, plasmadiscovery41, for oncology biomarker discovery and qualification. The assay simultaneously measures 41 human plasma proteins that are thought to have potential as biomarkers in cancer, particularly breast, prostate and lung cancers. The launch of plasmadiscovery41 is part of NextGen Sciences strategy of becoming a leading player in the growing oncology and central nervous system (CNS) biomarker markets.

NextGen's assay is based upon its multiple reaction monitoring (MRM) mass spectrometry platform, and generates high quality reproducible data that companies can use in their drug and diagnostic development programmes. In addition to the cancer focus, the assay can be used for early-stage biomarker discovery and qualification in other disease areas. NextGen expects to continue to add proteins to the plasmadiscovery41 assay, in addition to developing other disease-focused assay panels, both as proprietary products and with other companies through partnerships and collaborations.

Klaus Rosenau, Chairman and CEO of NextGen Group, commented, 'The release of plasmadiscovery41 is a defining first step in the development of NextGen Sciences' biomarker business, following its recent reorganization. It demonstrates that we are now delivering on our plans to develop multiplex protein assays and will help to establish the company as a market leader in biomarker discovery and qualification using its MRM technology. Importantly, its enables us to aggressively target increasing market share from the $600m mass spectrometry based biomarker discovery market. We believe that pharmaceutical, biotechnology and diagnostics companies need high-quality assays relevant to their disease areas to inform their decision-making processes, and NextGen Sciences expects to launch more such products in the future.'.

- ENDS -

For more information please contact :

NextGen Group

Klaus Rosenau, Chairman and CEO

[e-mail]

[phone]

Seymour Pierce

Jonathan Wright, Nicola Marrin

[phone]

[lady gaga] 15/3/2011 14:05

We got a plug here.

March 2011's Penny Shares to Watch...

This month's penny shares to watch:



•The mounting backlash against miners...

AVOCET (AVM), NYOTA MINERALS (NYO), AFRICAN AURA (AAAM), FORTE ENERGY (FTE) and PETRA DIAMONDS (PDL)



•Here comes the Biotech Mania...

SAREUM HOLDINGS (SAR), PHYSIOMICS (PYC), NEXTGEN (NGG), VALIRX (VAL), ANTISOMA (ASM) and VERONA PHARMA (VRP)

[stephanie_m] 13/3/2011 23:10

When the turnover is low the spread can by high. However in recents weeks the spread has been as low as 1% or less.
Developments are expected by end of June and I see the current price as an excellent opportunity to increase my holding. A small % of the shares are in free float.

s

[lokesh8] 13/3/2011 13:27

George57,

Many thanks for your explanation, looks like only big ones seem to have minimal spread ie: Vodafone has a spread of 0.0/ 0.1...and RBS..

[george57] 13/3/2011 11:51

Lokesh8,

What you are describing is a very common problem with not only NGG but also the rest of AIM stocks.

What you see on your screen is probably not the full story, for instance you might see 0.35p to buy, but you can actually buy at say 0.32p, or it is showing 0.28p to sell but you can in fact get 0.29p. It tends to work that way with most AIM stocks.

What you also have to remember is that some of these stocks move very quickly once either news or buying arrives, and the MMs cover themselves.

It doesn't matter if you are buying any stock whether it is a FTSE100 stock or a tiddler on AIM, as soon as you buy you are down, you are gambling that the bid price will rise sufficiently to exceed the buy price, that way you will be in profit.

Basically share dealing is one big casino or betting shop. I hope this helps.